Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy

被引：115

作者：

Repa, A

Grangette, C

Daniel, C

Hochreiter, R

Hoffmann-Sommergruber, K

Thalhamer, J

Kraft, D

Breiteneder, H

Mercenier, A

Wiedermann, U

机构：

[1] Univ Vienna, Sch Med, Dept Pathophysiol, Div Specif Prophylaxis & Trop Med,AKH EBO3Q, A-1090 Vienna, Austria

[2] Inst Pasteur, Lab Bacteriol Ecosyst, F-59019 Lille, France

[3] Salzburg Univ, Inst Chem & Biochem, A-5020 Salzburg, Austria

[4] Nestle Res Ctr, Dept Biosci, CH-1000 Lausanne, Switzerland

来源：

VACCINE | 2003年 / 22卷 / 01期

基金：

奥地利科学基金会;

关键词：

type I allergy; animal model; lactic acid bacteria; immunomodulation;

D O I：

10.1016/S0264-410X(03)00528-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recent epidemiological studies and clinical trials suggest a possible role of certain lactic acid bacteria (LAB) strains in the prevention of allergic diseases. In this study, we aimed at evaluating the immunomodulatory potential of two LAB strains, Lactococcus lactis and Lactobacillus plantarum, for prophylaxis and therapy of allergic immune responses. Both LAB strains-induced high levels of IL-12 and IFN-gamma in naive murine spleen cell cultures. Intranasal co-application with recombinant Bet v 1, the major birch pollen allergen, prior or after allergic sensitization, led to increased levels of allergen-specific IgG2a antibodies and in vitro IFN-gamma production, indicating a shift towards Th1 responses. Successful immunomodulation by the mucosal pre-treatment was further demonstrated by suppression of allergen-induced basophil degranulation. We conclude that these LAB strains in combination with an allergen could be promising candidates for mucosal vaccination against type I allergy. (C) 2003 Elsevier Ltd. All rights reserved.

引用

页码：87 / 95

页数：9

共 48 条

[1] The genetics and complexity of allergy and asthma [J].

Barnes, KC ;

Marsh, DG .

IMMUNOLOGY TODAY, 1998, 19 (07) :325-332

[2] Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema:: ISAAC [J].

Beasley, R ;

Keil, U ;

von Mutius, E ;

Pearce, N ;

Aït-Khaled, N ;

Anabwani, G ;

Anderson, HR ;

Asher, MI ;

Björkstéin, B ;

Burr, ML ;

Clayton, TO ;

Crane, J ;

Ellwood, P ;

Lai, CKW ;

Mallol, J ;

Martinez, FD ;

Mitchell, EA ;

Montefort, S ;

Robertson, CF ;

Shah, JR ;

Sibbald, B ;

Stewart, AW ;

Strachan, DP ;

Weiland, SK ;

Williams, HC .

LANCET, 1998, 351 (9111) :1225-1232

[3]

Björkstén B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x

[4]

Bousquet J, 1998, ALLERGY, V53, P4

[5] Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells [J].

Christensen, HR ;

Frokiær, H ;

Pestka, JJ .

JOURNAL OF IMMUNOLOGY, 2002, 168 (01) :171-178

[6] A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections [J].

Drachenberg, KJ ;

Wheeler, AW ;

Stuebner, P ;

Horak, F .

ALLERGY, 2001, 56 (06) :498-505

[7] Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen [J].

Ebner, C ;

Siemann, U ;

Bohle, B ;

Willheim, M ;

Wiedermann, U ;

Schenk, S ;

Klotz, F ;

Ebner, H ;

Kraft, D ;

Scheiner, O .

CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (09) :1007-1015

[8]

FULLER R, 1989, J APPL BACTERIOL, V66, P365

[9]

GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245

[10]

GASSON MJ, 1983, J BACTERIOL, V154, P1

← 1 2 3 4 5 →